Compare Davita Inc (DVA) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs FTAI Aviation Ltd — how do they compare? Davita Inc trades at $228.1 (market cap $14.92B), while FTAI Aviation Ltd trades at $208.16 (market cap $21.17B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays a 0.73% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | FTAI | |
|---|---|---|
Market Cap | $14.92B | $21.17B |
Sector | Health | Industrials |
52-Week High | $235.71 | $310.04 |
52-Week Low | $103.87 | $109.92 |
Enterprise Value | $27.47B | $24.21B |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
FTAI Aviation trades at $209.88, down 7.68% today, amid a bearish technical signal. The stock has missed earnings estimates for three consecutive quarters, though revenue and net income remain robust. Recent news highlights strategic collaborations and growth in data center power solutions. Analyst consensus is unanimously bullish with 18 buy ratings.
The outlook is supported by strong fundamentals and growth initiatives, but risks include earnings misses and high valuation multiples. The stock's near-term performance hinges on Q2 2026 results and execution of new business segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
